This anonymous comment deserves top-of-page mention:
. . . .More interesting stuff from the ARBITER-6 paper just published in JACC. Figure 1 tells a huge story! Shows that the greater the exposure (measured by the product of dose/day, adherence, and time on therapy) to ezetimibe, the more atherosclerosis progresses -- and the the greater the exposure to niacin, the more athero regresses. This is very damning for ezetimibe, as it takes any sidebar question of relationship to lipids, etc out of the equation, and just simply describes what happens the more drug exposure over time you have.
Does anyone else find it odd that Merck is so silent on this new publication? Quite the contrast from the Merck PR spin blitzkrieg back in November. C'mon Dick, where's that NYT letter-to-the editor about this new paper??? Peter Kim??? Dick Clark??? All you other shills on the Merck gravy train??? This is a material development in the Zetia/Vytorin story. . . .
April 22, 2010 @ 8:48 AM